19 December 2024NewsAmericasDanielle Burns Principal Philips Ormonde Fitzpatrick, David Longmuir Principal Philips Ormonde Fitzpatrick, Jason Murata Partner Axinn Veltrop & Harkrider, Michael Davitz Partner Leason Ellis
WATCH: Intersectionality of IP with licensing and commercialisation
Speakers from Philips Ormonde Fitzpatrick, Axinn Veltrop & Harkrider, and Leason Ellis discuss how IP rights are not merely legal tools but strategic assets that can significantly influence a product’s lifecycle, from development to market.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
28 April 2026 BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.
23 April 2026 The US pharma giant is spending up to $1 billion to build an end-to-end biosimilar platform and is counting on a decade of expiring biologic patents to make it pay off.
23 April 2026 Plaintiff alleges that a $6 billion rival probed its records system via a long-term customer, using confidential information to develop its product in the behavioural health tech space.